VERA
Vera Therapeutics, Inc.Company Information
- Company Name
- Vera Therapeutics, Inc.
- CIK
- CIK0001831828
- Category
- Large accelerated filer
- Ticker: Exchange
- VERA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- VERA
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-12-11
- Last sale
- 2026-09-15
- Shares purchased (TTM)
- 5,882
- Shares sold (TTM)
- 262,555
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 74,255,823
- Shares outstanding
- 71,838,008
- Ownership
- 103.37%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- 13.65%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 49 | 114 | 355 | 58 | 49 | 55 | 93 | 27 | 25 | 69 | 46 | 27 | ||||||
| Marketable Securities Current | 450 | 482 | 360 | 440 | 508 | 535 | 548 | 326 | 359 | 335 | 115 | 132 | ||||||
| Prepaid Expense And Other Assets Current | 28 | 19 | 14 | 14 | 15 | 16 | 10 | 11 | 10 | 13 | 11 | 12 | ||||||
| Assets Current | 527 | 616 | 729 | 511 | 571 | 606 | 651 | 364 | 395 | 416 | 172 | 172 | ||||||
| Restricted Cash Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Other Assets Noncurrent | 5 | 6 | - | - | - | - | - | - | - | - | - | - | ||||||
| Property Plant And Equipment Net | - | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 533 | 622 | 735 | 518 | 579 | 610 | 656 | 369 | 397 | 419 | 176 | 176 | ||||||
| Operating Lease Right Of Use Asset | - | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 2 | 2 | 3 | 3 | ||||||
| Prepaid Expense And Other Assets Noncurrent | - | - | 3 | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Marketable Securities Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 15 | 14 | 22 | 18 | 13 | 9 | 8 | 5 | 5 | 5 | 11 | 12 | ||||||
| Operating Lease Liability Current | - | - | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | ||||||
| Accrued Liabilities Current | 34 | 31 | 31 | 23 | 20 | 11 | 16 | 20 | 12 | 7 | 9 | 10 | ||||||
| Liabilities Current | 48 | 45 | 53 | 42 | 34 | 22 | 25 | 26 | 18 | 15 | 22 | 25 | ||||||
| Long Term Debt | 75 | 75 | 75 | 75 | 74 | 51 | 51 | 50 | 50 | 50 | 50 | 25 | ||||||
| Operating Lease Liability Noncurrent | - | - | 2 | 2 | 2 | 2 | 2 | 3 | 0 | 1 | 1 | 2 | ||||||
| Other Liabilities Noncurrent | 2 | 2 | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 125 | 122 | 130 | 119 | 110 | 75 | 79 | 80 | 69 | 66 | 74 | 52 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Additional Paid In Capital Common Stock | 1,399 | 1,382 | 1,365 | 1,068 | 1,057 | 1,047 | 1,038 | 706 | 699 | 691 | 410 | 407 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 1 | 1 | 1 | 1 | 0 | 1 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -991 | -882 | -761 | -670 | -589 | -513 | -461 | -418 | -371 | -337 | -309 | -283 | ||||||
| Stockholders Equity | 408 | 500 | 605 | 399 | 468 | 535 | 577 | 289 | 328 | 354 | 102 | 124 | ||||||
| Liabilities And Stockholders Equity | 533 | 622 | 735 | 518 | 579 | 610 | 656 | 369 | 397 | 419 | 176 | 176 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialVera Therapeutics, Inc. (VERA) — SEC Financial Statements & Analysis
Vera Therapeutics, Inc. (VERA) is a pharmaceutical preparations company, incorporated in DE. Vera Therapeutics, Inc. trades on Nasdaq as: VERA. Vera Therapeutics, Inc. (VERA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, Vera Therapeutics, Inc. carries a market cap of $3.08B, a P/E ratio of -7.67x, a P/B ratio of 7.56x, an enterprise value of $3.11B, and an EV/EBITDA multiple of -7.49x. On profitability, it posts a Return on Equity (ROE) of -91.75%, a Return on Assets (ROA) of -72.32%, and a Return on Invested Capital (ROIC) of -89.63%. Per share, it reports EPS of $-5.59, diluted EPS of $-5.59, free cash flow per share of $-4.72, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 84.12% year-over-year and EPS growth of 63.49% year-over-year. On the balance sheet, it maintains a current ratio of 10.92x, a quick ratio of 10.33x, working capital of $479.17M, a debt-to-equity ratio of 0.31x, a debt ratio of 0.23, an interest coverage ratio of -55.17x, free cash flow of $-338.91M (TTM), and net debt of $26.35M. Figures sourced from SEC EDGAR.
- Market Cap
- $3.08B
- P/E TTM
- -7.67x
- EPS TTM
- $-5.59
- P/B TTM
- 7.56x
- ROE TTM
- -91.75%
- ROA TTM
- -72.32%
- Debt To Equity
- 0.31x
- Free Cash Flow TTM
- $-338.91M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Vera Therapeutics, Inc. in?
Vera Therapeutics, Inc. (VERA) operates in the Pharmaceutical Preparations industry.
What exchange does VERA trade on?
Vera Therapeutics, Inc. (VERA) trades on the Nasdaq.
Where is Vera Therapeutics, Inc. incorporated?
Vera Therapeutics, Inc. is incorporated in DE.
When was Vera Therapeutics, Inc. (VERA)'s most recent SEC filing?
Vera Therapeutics, Inc. (VERA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is VERA's market cap?
Vera Therapeutics, Inc. (VERA) has a market capitalization of $3.08B as of 2026-06-30.
What is VERA's EPS (earnings per share)?
Vera Therapeutics, Inc. (VERA)'s trailing twelve month EPS is $-5.59 as of 2026-06-30.
What is VERA's ROE (return on equity)?
Vera Therapeutics, Inc. (VERA)'s trailing twelve month Return on Equity (ROE) is -91.75% as of 2026-06-30.
What is VERA's ROA (return on assets)?
Vera Therapeutics, Inc. (VERA)'s trailing twelve month Return on Assets (ROA) is -72.32% as of 2026-06-30.
What is VERA's ROIC (return on invested capital)?
Vera Therapeutics, Inc. (VERA)'s trailing twelve month Return on Invested Capital (ROIC) is -89.63% as of 2026-06-30.
What is VERA's EV/EBITDA?
Vera Therapeutics, Inc. (VERA)'s trailing twelve month EV/EBITDA is -7.49x as of 2026-06-30.